知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

93 records (took 0.027 seconds)

    Method for aiding differential diagnosis of stroke
    81.
    发明授权
    Method for aiding differential diagnosis of stroke 有权

    公开(公告)号：US10753948B2

    公开(公告)日：2020-08-25

    申请号：US14895724

    申请日：2014-06-04

    Applicant: Randox Laboratories Ltd.

    Inventor： Ivan McConnell ,  John Lamont ,  Peter Fitzgerald ,  Konstantinos Makris

    IPC: G01N33/68

    Abstract: The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke.

    Kidney disease biomarker
    82.
    发明授权
    Kidney disease biomarker 有权

    公开(公告)号：US10444248B2

    公开(公告)日：2019-10-15

    申请号：US14421382

    申请日：2013-08-12

    Applicant: Randox Laboratories Ltd.

    Inventor： Ivan McConnell ,  Stephen Peter Fitzgerald ,  John Lamont ,  Claran Richardson

    IPC: G01N33/48 ,  G01N33/68 ,  C12N9/10 ,  G01N33/70 ,  G01N33/92 ,  C07K14/81 ,  C07K14/475 ,  G01N33/573

    Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.

    CHEMILUMINESCENCE DETECTOR
    83.
    发明申请
    CHEMILUMINESCENCE DETECTOR 审中-公开

    公开(公告)号：US20190025221A1

    公开(公告)日：2019-01-24

    申请号：US16069492

    申请日：2017-01-13

    Applicant: Randox Laboratories Ltd.

    Inventor： Stuart Jackson ,  Ivan McConnell ,  Peter Fitzgerald

    IPC: G01N21/76

    Abstract: The present invention provides a chemiluminescence detector, which comprises an image capture device sensitive to chemiluminescence located within a container. The container has an array of apertures located in a field of view of the image capture device, and each aperture is defined by a through-bore in a wall of the container. The exterior of the container is engagable with a plurality of sample holders, each sample holder being in alignment with a respective aperture when engaged with the exterior of the container. The passage of light into the container through each aperture is restrictable by a closure device, passage of light into the container through the apertures is thereby controllable.

    Method for aiding diagnosis of Alzheimer's disease
    86.
    发明授权
    Method for aiding diagnosis of Alzheimer's disease 有权

    公开(公告)号：US09880178B2

    公开(公告)日：2018-01-30

    申请号：US14431557

    申请日：2013-10-03

    Applicant: Randox Laboratories Ltd.

    Inventor： Ellen Umlauf ,  Maria Zellner

    IPC: G01N33/53 ,  G01N33/567 ,  G01N33/68 ,  G06F19/18 ,  G06F19/00

    CPC classification number: G01N33/6896 ,  G01N2333/4712 ,  G01N2333/775 ,  G01N2333/90 ,  G01N2333/90638 ,  G01N2333/91085 ,  G01N2800/2821 ,  G06F19/18 ,  G16H50/20

    Abstract: The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient comprising: (i) determining the number of alleles of ApoE4 in the patient's genome; (ii) determining the combined expression level of at least three platelet proteins in a platelet sample from the patient; and (iii) comparing the resulting value of step (ii) to a control value, wherein the at least three platelet proteins include at least one isoform of alpha-tropomyosin containing exon 1a and at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 or mutant GSTO-1, wherein a result higher than the control value is indicative of Alzheimer's disease.The invention also provides a solid support comprising one or more ligands of at least one isoform of alpha-tropomyosin containing exon 1a, and one or more ligands of at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 protein and/or mutant GSTO-1 protein immobilized thereon.

    LIQUID SAMPLE COLLECTION DEVICE
    87.
    发明申请
    LIQUID SAMPLE COLLECTION DEVICE 审中-公开

    公开(公告)号：US20170128051A1

    公开(公告)日：2017-05-11

    申请号：US15321112

    申请日：2015-06-15

    Applicant: Randox Laboratories Ltd.

    Inventor： Stuart Jackson ,  Ivan McConnell ,  John Lamont ,  Stephen Peter Fitzgerald

    IPC: A61B10/00 ,  A61F5/441

    CPC classification number: A61B10/007 ,  A61F5/441

    Abstract: A liquid sample collection device is provided. The liquid sample collection device comprises a housing including a liquid collection chamber, and a liquid supply conduit extending from an inlet port and in use generally downwardly to the collection chamber, wherein the collection chamber includes an air vent port located such that in use liquid supplied to the collection chamber through the liquid supply conduit displaces air through the air vent port, and wherein the liquid supply conduit follows a meandering path including at least one air trap section defined at the junction between portions of the conduit extending with upward and downward components respectively, whereby in use once the air vent port is closed, air is displaced along the liquid supply conduit until it is trapped by the air trap section thereby preventing further liquid flow through the conduit.

    ASSAY FLUID DELIVERY SYSTEM
    89.
    发明申请
    ASSAY FLUID DELIVERY SYSTEM 有权
    测定流体输送系统

    公开(公告)号：US20160296930A1

    公开(公告)日：2016-10-13

    申请号：US15038024

    申请日：2014-11-19

    Applicant: RANDOX LABORATORIES LTD

    Inventor： Jonathan Matear ,  Robson Pang ,  Stuart Jackson ,  David Sloan

    IPC: B01L3/00

    CPC classification number: B01L3/50273 ,  B01L3/502715 ,  B01L3/527 ,  B01L2200/027 ,  B01L2200/04 ,  B01L2200/0605 ,  B01L2200/0621 ,  B01L2200/10 ,  B01L2200/16 ,  B01L2300/0816 ,  B01L2300/123 ,  B01L2400/0478 ,  B01L2400/0481 ,  B01L2400/0487 ,  F04B9/042 ,  G01N35/00029 ,  G01N35/1002 ,  G01N2035/00148 ,  G01N2035/0486

    Abstract: There is provided an assay fluid delivery system comprising an array of fluid reservoirs (62), each of which is selectively actuatable to deliver a respective fluid to a fluid channel structure; and a fluid delivery control system (50) comprising a plurality of reciprocally mounted actuators, each associated with a respective reservoir and being movable between a retracted position and an actuating position at which it causes fluid to be delivered from the corresponding reservoir, a plurality of cams (22) with different profiles mounted on a common, rotatable cam shaft (6), each cam being engaged with a respective one of the actuators whereby rotation of the cams causes movement of the corresponding actuators between the retracted and actuating positions, and a motor coupled to the cam shaft for rotating the cam shaft, wherein the cams are shaped relative to one another so as to cause the corresponding actuators to actuate the reservoirs in a predetermined sequence and for predetermined respective times.

    Abstract translation: 提供了一种分析流体递送系统，其包括流体储存器阵列（62），每个流体储存器可选择性地致动以将相应的流体输送到流体通道结构; 以及流体输送控制系统（50），其包括多个往复安装的致动器，每个致动器与相应的储存器相关联并且可在缩回位置和致动位置之间移动，在该致动位置处，使得流体从相应的储存器输送， 具有不同轮廓的凸轮（22）安装在共同的可旋转的凸轮轴（6）上，每个凸轮与相应的一个致动器接合，由此凸轮的旋转引起相应致动器在缩回位置和致动位置之间的移动， 马达耦合到凸轮轴用于旋转凸轮轴，其中凸轮相对于彼此成形，以使相应的致动器以预定顺序并且预定的各个时间致动储存器。

    DIAGNOSIS AND RISK STRATIFICATION OF BLADDER CANCER
    90.
    发明申请
    DIAGNOSIS AND RISK STRATIFICATION OF BLADDER CANCER 有权
    乳腺癌的诊断和风险分析

    公开(公告)号：US20150269311A1

    公开(公告)日：2015-09-24

    申请号：US14435991

    申请日：2013-10-16

    Applicant: RANDOX LABORATORIES LTD.

    Inventor： Mark William Ruddock ,  Cherith N. Reid ,  Kate E. Williamson ,  Frank Emmert-Streib ,  John V. Lamont ,  Peter Fitzgerald

    IPC: G06F19/18 ,  G06F19/24 ,  G06F19/00 ,  G01N33/574

    CPC classification number: G06F19/18 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2333/4737 ,  G01N2333/4742 ,  G01N2333/475 ,  G01N2333/485 ,  G01N2333/523 ,  G01N2333/525 ,  G01N2333/5406 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/545 ,  G01N2333/55 ,  G01N2333/70578 ,  G01N2333/70596 ,  G01N2333/7151 ,  G01N2333/7452 ,  G01N2333/928 ,  G01N2333/96433 ,  G01N2333/96494 ,  G01N2333/988 ,  G01N2400/00 ,  G06F19/00 ,  G06F19/24 ,  G16H50/30

    Abstract: The invention provides a method of defining the likelihood of a subject having bladder cancer, comprising the steps of: (A) assessing the subject's likelihood of having bladder cancer by: i. identifying at least one sub-population group appropriate to the subject; ii. determining the level of one or more biomarkers selected according to the sub-population group in a sample obtained from the subject; iii. inputting each of the biomarker values into an algorithm to produce an output value; and iv. correlating the output value with the likelihood of the subject having bladder cancer, wherein the sub-population group is selected according to smoking habits, gender, presence/absence of stone disease, history of benign prostate enlargement (BPE) or prescription of anti-hypertensive, anti-platelet and/or anti-ulcer medication, and (B) determining the subject's stratified risk level of serious disease by: v. determining the level of one or more biomarkers specific for one or more risk classifiers defined using Random Forest Classifiers (RFC), logistic regression or another appropriate systems biology or statistical approach in a sample obtained from the subject, vi. inputting each of the biomarker values into an algorithm or algorithms to produce an output value; and vii. correlating the output value with a stratified risk level of underlying serious disease, wherein the likelihood of having bladder cancer is combined with the stratified risk level of having serious disease, wherein the risk of having bladder cancer and/or serious disease is categorised as: high-risk bladder cancer requiring immediate cystoscopy; low-risk bladder cancer requiring urgent cystoscopy; high-risk control requiring close evaluation and further investigation; or low-risk control requiring primary care monitoring.

    Abstract translation: 本发明提供了一种定义患有膀胱癌的受试者的可能性的方法，包括以下步骤：（A）通过以下步骤评估受试者患膀胱癌的可能性：i。 识别适合于该受试者的至少一个亚群体群体; ii。 确定从受试者获得的样品中根据亚群体组选择的一种或多种生物标志物的水平; iii。 将每个生物标记值输入到算法中以产生输出值; 和iv。 将输出值与患有膀胱癌的患者的可能性相关联，其中根据吸烟习惯，性别，存在/不存在石头疾病，良性前列腺增生病史（BPE）或抗高血压药物处方选择亚群体组 ，抗血小板和/或抗溃疡药物，以及（B）通过以下方式确定受试者的严重疾病分层风险水平：v。确定一个或多个特定于使用随机森林分类器定义的风险分类器的生物标志物的水平 RFC），逻辑回归或从该主题获得的样本中的其他适当的系统生物学或统计学方法，vi。 将每个生物标记值输入算法或算法以产生输出值; 和vii。 将输出值与潜在严重疾病的分层风险水平相关联，其中膀胱癌的可能性与具有严重疾病的分层风险水平相结合，其中具有膀胱癌和/或严重疾病的风险被分类为：高 膀胱癌需要立即膀胱镜检查; 低危膀胱癌需要紧急膀胱镜检查; 高风险控制需要进行密切的评估和进一步的调查; 或需要初级保健监测的低风险控制。

Patent Agency Ranking